. Author manuscript; available in PMC: 2018 Apr 1.

Published in final edited form as: Pharmacogenet Genomics. 2017 Apr;27(4):143–154. doi: 10.1097/FPC.0000000000000269

Table 2.

Nicotine pharmacokinetic parameters by UGT2B10 FMO3 and OCT2 genotypes among individuals with reduced CYP2A6 activity (n=23)

Genotype		Half-life^c	Cmax^c	AUC^c	Non-renal CL^c	Total CL^c

		Mean^b (SD)	Mean^b (SD)	Mean^b (SD)	Mean^b (SD)	Mean^b (SD)
UGT2B10	AA (6)^d	130 (29)	21.4 (5.6)	2.86 (0.57)	1.09 (0.32)	1.16 (0.33)
(rs116294140)	AC (12)	157 (47)	18.8 (7.5)	3.19 (1.29)	1.27 (0.43)	1.31 (0.44)
	CC (5)	156 (32)	34.3 (21.3)	3.36 (0.93)	0.99 (0.20)	1.04 (0.18)
	P-value	0.49^a	0.14^a	0.76^a	0.22^a	0.32^a

UGT2B10	GG (20)	150 (43)	23.6 (13.1)	3.21 (1.10)	1.14 (0.36)	1.19 (0.37)
(rs61750900)	GT (3)	149 (9)	17.7 (6.7)	2.70 (0.48)	1.33 (0.48)	1.36 (0.44)
	TT (0)	NA	NA	NA	NA	NA
	P-value	0.93^a	0.39^a	0.41^a	0.41^a	0.52^a

FMO3	GG (4)	157 (50)	27.0 (8.5)	3.73 (1.50)	0.98 (0.23)	1.01 (0.24)
(rs2266782)	GA (9)	139 (32)	19.2 (5.5)	2.62 (0.43)	1.33 (0.27)	1.38 (0.29)
	AA (10)	156 (45)	24.5 (17.5)	3.38 (1.12)	1.09 (0.45)	1.13 (0.44)
	P-value	0.59^a	0.34^a	0.10^a	0.13^a	0.11^a

OCT2	CC (19)	147 (43)	20.6 (8.3)	3.13 (1.10)	43.0 (38.4)^e	1.24 (0.39)
(rs316019)	CA (4)	162 (20)	33.7 (23.3)	3.23 (0.84)	60.0 (15.1)^e	1.07 (0.30)
	AA (0)	NA	NA	NA	NA	NA
	P-value	0.29^a	0.12^a	0.57^a	0.11^a	0.33^a

P-values are based on Mann-Whitney test or Kruskal-Wallis test with Bonferroni correction for multiple testing.

Arithmetic means are presented.

Nicotine (d2) half-life is measured in min, Cmax in ng/ml, AUC in min*µg/ml, and non-renal and total clearance in L/min.

Genotype frequencies are presented in the brackets.

OCT2 variation was examined with respect to nicotine renal as opposed to non-renal clearance (ml/min).

Abbreviation: SD, standard deviation; AUC, area under the curve; CL, clearance.